PCa Commentary | Volume 163 – March 2022
This Commentary looks at how the Decipher assay assists in decision-making for how to treat patients with prostate cancer.
Read MoreSelect Page
Posted by Edward Weber, MD | Mar 2022
This Commentary looks at how the Decipher assay assists in decision-making for how to treat patients with prostate cancer.
Read MorePosted by Edward Weber, MD | Feb 2022
This Commentary gives an update on patient selection and monitoring for prostate cancer active surveillance.
Read MorePosted by Edward Weber, MD | Jan 2022
This Commentary looks at bipolar androgen therapy (BAT) as a treatment option for metastatic castration-resistant prostate cancer (mCRPC).
Read MorePosted by Edward Weber, MD | Dec 2021
This Commentary looks at gene mutations in the BRCA Family and PARP inhibition therapy for advanced prostate cancer.
Read MorePosted by Edward Weber, MD | Nov 2021
This Commentary looks at the application of genomics to therapy selection for patients metastatic hormone-sensitive prostate cancer (mHSPC).
Read More